GlassScriptPhysician profile
Cecilia Ross
NPI 1457304065
$34,115.53
in general payments reported to CMS, 2019-2025
35 companies · $6,754 in 2025
The $6,754 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,270 · 2022: $6,181 · 2023: $11K · 2024: $6,701 · 2025: $6,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Consulting Fee: $3,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,752 · Travel and Lodging: $1,218 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,997.80 |
| Consulting Fee | $3,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,751.88 |
| Travel and Lodging | $1,217.59 |
| Education | $197.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $7,731.36 | 2023-2025 | Zoryve |
| Incyte Corporation | $3,947.49 | 2021-2025 | Opzelura, Opzelura |
| Abbvie INC. | $2,836.24 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,034.86 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $1,637.94 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,383.94 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $1,321.44 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $1,320.82 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $1,293.78 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,288.27 | 2021-2025 | Siliq, Cabtreo, Jublia |
| Genzyme Corporation | $1,283.93 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,202.44 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $1,202.31 | 2021-2025 | Tremfya, Stelara, Remicade |
| Journey Medical Corporation | $975.97 | 2021-2025 | Qbrexza |
| Novartis Pharmaceuticals Corporation | $857.27 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $793.15 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $665.51 | 2021-2025 | Otezla, Otezla, Enbrel |
| Dermavant Sciences, INC. | $457.35 | 2023-2024 | Vtama |
| Organon LLC | $366.31 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $309.88 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.42 | 2023-2025 | Spevigo |
| Almirall LLC | $168.95 | 2021-2025 | Klisyri, Seysara |
| Novo Nordisk INC | $121.77 | 2021 | |
| Mayne Pharma Commercial LLC | $115.24 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $93.77 | 2023-2024 | Neo-Synalar, Clindacin Etz |
| Epi Health, LLC | $88.44 | 2021-2022 | |
| Strata Skin Sciences, INC. | $86.70 | 2023 | Xtrac |
| Janssen Scientific Affairs, LLC | $76.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $67.29 | 2021-2025 | |
| Fresenius Kabi USA, LLC | $54.59 | 2023-2024 | Idacio |
| Verrica Pharmaceuticals INC. | $45.05 | 2024 | Ycanth |
| Genentech USA, INC. | $41.65 | 2021-2023 | Erivedge |
| Dermira, INC. | $25.46 | 2021 | |
| Botanix Sb INC | $17.47 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.